Link Between PSA Response and Survival Outcomes Supports Use of Darolutamide Plus ADT/Docetaxel as a SOC in mHSPC

Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.

Related Keywords

Canada ,United States ,Montreal ,Quebec ,American ,Fred Saad ,Raymond Garneau ,Montreal Cancer Institute ,University Of Montreal Hospital Center ,American Urological Association ,University Of Montreal ,Research Center ,Department Of Surgery ,Urological Association ,Annual Meeting ,Montreal Hospital Center ,Montreal Cancer ,Raymond Garneau Chair ,Prostate Cancer ,Arasens Trial ,Psa Response ,Survival Outcomes ,Metastatic Hormone Sensitive Prostate Cancer ,Triplet Regimens ,Aua Meeting ,D ,Rcs ,